title: Pharmacogenetics of hepatitis C.
abstract: Recent discoveries have highlighted the influence of host genomics on hepatitis C virus (HCV) infection outcomes. As a result, our views on hepatitis C pathogenesis and therapeutic approaches have been transformed. The recognition of the impact of single-nucleotide polymorphisms (SNPs) of the genes interleukin 28B (IL28B), inosine triphosphatase (ITPA) and low-density lipoprotein cholesterol receptor (LDLR) may lead to refinements in the pharmacogenomic prediction of antiviral response and drug-related toxicities and favour the discovery of new therapeutic targets for hepatitis C. Although the relevance of host genetics may be less in the setting of very potent new direct-acting antivirals (DAAs), genetic markers may continue to aid decision making regarding the length of therapy. Moreover, in several populations, such as HIV/HCV-coinfected patients, current therapy with peginterferon-α/ribavirin will continue in use for most patients, and thus host factors will retain their predictive value for treatment outcomes for a while.
authors.affiliation: Infectious Diseases Department, Hospital Carlos III, Madrid, Spain. vsoriano@dragonet.es
authors.forename: Vincent
authors.initials: V
authors.lastname: Soriano
authors.forename: Eva
authors.initials: E
authors.lastname: Poveda
authors.forename: Eugenia
authors.initials: E
authors.lastname: Vispo
authors.forename: Pablo
authors.initials: P
authors.lastname: Labarga
authors.forename: Norma
authors.initials: N
authors.lastname: Rallón
authors.forename: Pablo
authors.initials: P
authors.lastname: Barreiro
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D010597:Pharmacogenetics; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents